Read More

Tevogen Bio Entered Into A Securities Purchase Agreement With An Investor Pursuant To Which The Investor Agreed To Purchase Shares Of Series A Preferred Stock Of The Company For An Aggregate Purchase Price Of $8M

On February 14, 2024, Tevogen Bio Holdings Inc. (the "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology,

TVGN

Read More

Bakkt Shelf Registration Statement Declared Effective By The SEC; Registration Statement Allows Bakkt, So Long As It Is Effective, To Raise Up To An Aggregate Of $150M Of Capital In One Or More Offerings Over The Subsequent 3-Years

Bakkt Holdings, Inc. ("Bakkt") (NYSE:BKKT) announced that its "universal shelf" registration statement on Form S-3 was declared effective by the Securities and Exchange Commission (the "SEC") on February 14, 2024. This

BKKT